phrykt

Praxis Precision Medicines, Inc. (PRAX): who owns it and who trades it

As of Nov 16, 2026, PRAX insiders reported 18 open-market sales worth $11.1M and no purchases in the last 12 months, with 33% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alex Nemiroff (General Counsel and Secr), with $4.9M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Praxis Precision Medicines

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Famous investors and Congress mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, PRAX insiders reported $0 of open-market purchases and $11.1M of sales. 33% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$11.1M
18 trades, 3 people
Sales under a 10b5-1 plan
33%
Share of sale value
Latest trade
Jun 24, 2026
Filed Jun 26, 2026

Purchases and sales by month

$3.6M$3.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 24, 2026Jill DeSimoneDirectorSale plan10$301.44$3KForm 4
Jun 24, 2026Jill DeSimoneDirectorSale plan1,279$314.90$403KForm 4
Jun 24, 2026Jill DeSimoneDirectorSale plan837$315.71$264KForm 4
Jun 24, 2026Jill DeSimoneDirectorSale plan504$313.66$158KForm 4
Jun 24, 2026Jill DeSimoneDirectorSale plan1,004$312.83$314KForm 4
Jun 24, 2026Jill DeSimoneDirectorSale plan2,854$311.91$890KForm 4
Jun 24, 2026Jill DeSimoneDirectorSale plan1,750$310.89$544KForm 4
Jun 24, 2026Jill DeSimoneDirectorSale plan999$309.38$309KForm 4
Jun 24, 2026Jill DeSimoneDirectorSale plan1,240$308.24$382KForm 4
Jun 24, 2026Jill DeSimoneDirectorSale plan683$306.77$210KForm 4
Jun 24, 2026Jill DeSimoneDirectorSale plan320$305.31$97.7KForm 4
Jun 24, 2026Jill DeSimoneDirectorSale plan120$303.13$36.4KForm 4
Nov 20, 2025Alex NemiroffGeneral Counsel and SecrSale9,100$194.30$1.8MForm 4
Nov 20, 2025Alex NemiroffGeneral Counsel and SecrSale977$193.23$189KForm 4
Nov 20, 2025Alex NemiroffGeneral Counsel and SecrSale13,339$192.53$2.6MForm 4
Nov 20, 2025Alex NemiroffGeneral Counsel and SecrSale1,714$190.86$327KForm 4
Nov 20, 2025Lauren MastrocolaPrincipal Accounting OffSale2,145$192.71$413KForm 4
Nov 20, 2025Lauren MastrocolaPrincipal Accounting OffSale11,455$191.96$2.2MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Alex NemiroffGeneral Counsel and Secretary–$4.9MNov 20, 2025
Jill DeSimoneDirector–$3.6MJun 24, 2026
Lauren MastrocolaPrincipal Accounting Officer–$2.6MNov 20, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PRAX short interest

High short interest. 15.1% of PRAX shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 13%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.21M PRAX shares were sold short, 15.1% of the shares outstanding, up 7.3% from the report before. At the average daily volume of 484,385 shares, buying them all back would take about 8.7 trading days (days to cover).

Shares short, % of all shares

15.1%May 15Oct 3015.4%

Days to cover

8.7May 15Oct 3016.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.21M15.07%+7%484,3858.7
Oct 15, 20263.92M14.05%-6%529,1207.4
Sep 30, 20264.19M15.00%+10%585,2847.2
Sep 15, 20263.80M13.59%+1%255,09414.9
Aug 31, 20263.74M13.40%+1%368,14610.2
Aug 14, 20263.71M13.30%+2%476,5767.8
Jul 31, 20263.66M13.10%-3%322,41611.3
Jul 15, 20263.76M13.50%-6%408,4629.2
Jun 30, 20263.99M14.30%+12%773,3505.2
Jun 15, 20263.57M12.80%-2%649,9495.5
May 29, 20263.65M13.10%-2%302,51612.1
May 15, 20263.71M13.30%-2%402,6619.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded PRAX

Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 0 sales of PRAX. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Sep 29, 2026, reported Oct 12, 2026.

Purchases 2Sales 0

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Sep 29, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfOct 12, 2026Report
Jul 30, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfSep 4, 2026Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Praxis Precision Medicines company events

Praxis Precision Medicines filed 19 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, auditor). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jul 7, 2026AnnouncementPraxis Precision Medicines, Inc. announced that the Company entered into a research collaboration and license agreement with Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems, to develop an iontophoretic transdermal patch for the delivery of… Filing
  4. Jul 2, 2026AuditorThe Audit Committee of the Board of Directors of Praxis Precision Medicines, Inc. approved the dismissal of Ernst & Young LLP as the Company's independent registered public accounting firm, effective as of that date. Filing
  5. Jun 29, 2026AnnouncementPraxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration notified the Company that it has extended by three months the review period for its New Drug Application for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies, setting… Filing
  6. Jun 22, 2026AnnouncementPraxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for elsunersen (PRAX-222), an antisense oligonucleotide for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of… Filing
  7. Jun 12, 2026VoteReported shareholder vote results. Filing
  8. Jun 1, 2026AnnouncementPraxis Precision Medicines, Inc. announced results from the Phase 2/3 POWER1 study evaluating vormatrigine in patients with focal onset seizures. Filing
  9. May 7, 2026ResultsReleased financial results. Filing
  10. Apr 14, 2026AnnouncementPraxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration has accepted for review its New Drug Application for ulixacaltamide HCl for the treatment of essential tremor in adults. Filing
  11. Apr 6, 2026AnnouncementPraxis Precision Medicines, Inc. is providing the following business updates: Elsunersen The Company announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with early-seizure onset SCN2A development and epileptic encephalopathy. Filing
  12. Feb 19, 2026ResultsReleased financial results. Filing
  13. Feb 10, 2026LeadershipAmended an earlier report. Praxis Precision Medicines, Inc. filed a Current Report on Form 8-K disclosing that the Board of Directors of the Company elected Jeffrey B. Kindler and Stuart A. Arbuckle to the Board, each as a Class II director, effective January 8, 2026. Filing
  14. Jan 8, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
  15. Jan 7, 2026AnnouncementPraxis Precision Medicines, Inc. entered into an underwriting agreement with Piper Sandler & Co., TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named in Schedule A thereto, relating to an underwritten offering of 2,212,000 shares of the… Filing
  16. Jan 6, 2026ResultsReleased financial results. Filing
  17. Dec 29, 2025AnnouncementPraxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for ulixacaltamide for the treatment of patients with essential tremor. Filing
  18. Dec 11, 2025AnnouncementPraxis Precision Medicines, Inc. announced the completion of a Type C meeting with the U.S. Food and Drug Administration and agreement to immediately convert the EMBRAVE3 registrational study of elsunersen in early-onset SCN2A developmental and epileptic encephalopathy into a single-arm study where… Filing
  19. Dec 8, 2025AnnouncementPraxis Precision Medicines, Inc. announced the successful completion of its pre-New Drug Application meeting with the U.S. Food and Drug Administration, including receipt of written feedback and an in-person meeting. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Praxis Precision Medicines financials

Famous investors that hold PRAX

2 of the 50 well-known investors we track reported holding PRAX in their latest 13F filing. The largest position is Ken Griffin's, worth $6.1M.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202621,080$6.1M0.0%+188%
Israel Englander · Millennium ManagementQ3 20267,339$2.1M0.0%+638%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PRAX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026ORBIS INVESTMENT MANAGEMENT LTD13G/A4.9%
Nov 16, 2026ORBIS INVESTMENT MANAGEMENT LTD13G/A4.9%
Nov 5, 2026FMR LLC13G/A9.2%
Nov 5, 2026FMR LLC13G/A9.2%

Questions about Praxis Precision Medicines, Inc. (PRAX) stock

Are PRAX insiders buying or selling?

In the last 12 months, PRAX insiders reported no open-market purchases and 18 sales worth $11.1M. The latest trade was on Jun 24, 2026. See every trade.

What is the short interest in PRAX?

As of Oct 30, 2026, 4.21M PRAX shares were sold short, 15.1% of the shares outstanding, up 7.3% from the report before. At the average daily volume of 484,385 shares, buying them all back would take about 8.7 trading days (days to cover). See the history.

Have members of Congress traded PRAX?

Yes. 1 member of Congress reported 2 purchases and 0 sales of PRAX since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.

Which famous investors hold PRAX?

2 of the 50 well-known investors we track reported PRAX in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $6.1M. See all holders.

Executive pay

Praxis Precision Medicines's chief executive was paid a total of $8.7M for the year ended Dec 31, 2025, down 35% from $13.4M the year before. In the last 12 months, Praxis Precision Medicines's executives and directors bought no stock on the open market and sold $11.1M.

Chief executive, total pay$8.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$55.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.